Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 31 of 31 entries
Sorted by: Best Match Show Resources per page
Fibroblast growth factor-10 and epithelial-mesenchymal transition in colorectal cancer.

EXCLI journal

Farajihaye Qazvini F, Samadi N, Saffari M, Emami-Razavi AN, Shirkoohi R.
PMID: 31611737
EXCLI J. 2019 Jul 17;18:530-539. doi: 10.17179/excli2018-1784. eCollection 2019.

As an inducer of epithelial-mesenchymal transition (EMT), fibroblast growth factor-10 (FGF-10) has a role in cell proliferation and differentiation in the embryo in addition to invasion and metastasis during carcinogenesis. In this study, we aimed to investigate the FGF-10...

Cite
Farajihaye Qazvini F, Samadi N, Saffari M, et al. Fibroblast growth factor-10 and epithelial-mesenchymal transition in colorectal cancer. EXCLI J. 2019;18:530-539doi: 10.17179/excli2018-1784.
Farajihaye Qazvini, F., Samadi, N., Saffari, M., Emami-Razavi, A. N., & Shirkoohi, R. (2019). Fibroblast growth factor-10 and epithelial-mesenchymal transition in colorectal cancer. EXCLI journal, 18530-539. https://doi.org/10.17179/excli2018-1784
Farajihaye Qazvini, Fatemeh, et al. "Fibroblast growth factor-10 and epithelial-mesenchymal transition in colorectal cancer." EXCLI journal vol. 18 (2019): 530-539. doi: https://doi.org/10.17179/excli2018-1784
Farajihaye Qazvini F, Samadi N, Saffari M, Emami-Razavi AN, Shirkoohi R. Fibroblast growth factor-10 and epithelial-mesenchymal transition in colorectal cancer. EXCLI J. 2019 Jul 17;18:530-539. doi: 10.17179/excli2018-1784. eCollection 2019. PMID: 31611737; PMCID: PMC6785779.
Copy Download .nbib Format: NLM
The Impact of Long-term Exposure to Low Levels of Inorganic Arsenic on the Hypomethylation of SEPT9 Promoter in Epithelial-Mesenchymal Transformed Colorectal Cancer Cell Lines.

International journal of molecular and cellular medicine

Rafiei G, Shirkoohi R, Saffari M, Salehipour P, Modarressi MH.
PMID: 32215264
Int J Mol Cell Med. 2019;8(2):130-138. doi: 10.22088/IJMCM.BUMS.8.2.130. Epub 2019 Aug 25.

Inorganic arsenicals are worldwide environmental contaminants that affect molecular characteristics in biological systems and lead to genomic and epigenomic instability as well as epithelial mesenchymal transition (EMT). In this study, we aimed to investigate whether low levels of sodium...

Cite
Rafiei G, Shirkoohi R, Saffari M, et al. The Impact of Long-term Exposure to Low Levels of Inorganic Arsenic on the Hypomethylation of SEPT9 Promoter in Epithelial-Mesenchymal Transformed Colorectal Cancer Cell Lines. Int J Mol Cell Med. 2019;8(2):130-138doi: 10.22088/IJMCM.BUMS.8.2.130.
Rafiei, G., Shirkoohi, R., Saffari, M., Salehipour, P., & Modarressi, M. H. (2019). The Impact of Long-term Exposure to Low Levels of Inorganic Arsenic on the Hypomethylation of SEPT9 Promoter in Epithelial-Mesenchymal Transformed Colorectal Cancer Cell Lines. International journal of molecular and cellular medicine, 8(2), 130-138. https://doi.org/10.22088/IJMCM.BUMS.8.2.130
Rafiei, Gholamreza, et al. "The Impact of Long-term Exposure to Low Levels of Inorganic Arsenic on the Hypomethylation of SEPT9 Promoter in Epithelial-Mesenchymal Transformed Colorectal Cancer Cell Lines." International journal of molecular and cellular medicine vol. 8,2 (2019): 130-138. doi: https://doi.org/10.22088/IJMCM.BUMS.8.2.130
Rafiei G, Shirkoohi R, Saffari M, Salehipour P, Modarressi MH. The Impact of Long-term Exposure to Low Levels of Inorganic Arsenic on the Hypomethylation of SEPT9 Promoter in Epithelial-Mesenchymal Transformed Colorectal Cancer Cell Lines. Int J Mol Cell Med. 2019;8(2):130-138. doi: 10.22088/IJMCM.BUMS.8.2.130. Epub 2019 Aug 25. PMID: 32215264; PMCID: PMC7081085.
Copy Download .nbib Format: NLM
Differential expression of .

EXCLI journal

Tavabe Ghavami TS, Irani S, Mirfakhrai R, Shirkoohi R.
PMID: 32636728
EXCLI J. 2020 Jun 05;19:750-761. doi: 10.17179/excli2020-1335. eCollection 2020.

Gastric cancer is the first cause of cancer-related death in males and the second in female patients in Iran. Advanced cancer is usually associated with distant metastasis, which is uncontrollable. This study was conducted to compare the expression of

Cite
Tavabe Ghavami TS, Irani S, Mirfakhrai R, et al. Differential expression of . EXCLI J. 2020;19:750-761doi: 10.17179/excli2020-1335.
Tavabe Ghavami, T. S., Irani, S., Mirfakhrai, R., & Shirkoohi, R. (2020). Differential expression of . EXCLI journal, 19750-761. https://doi.org/10.17179/excli2020-1335
Tavabe Ghavami, Toktam Sadat, et al. "Differential expression of ." EXCLI journal vol. 19 (2020): 750-761. doi: https://doi.org/10.17179/excli2020-1335
Tavabe Ghavami TS, Irani S, Mirfakhrai R, Shirkoohi R. Differential expression of . EXCLI J. 2020 Jun 05;19:750-761. doi: 10.17179/excli2020-1335. eCollection 2020. PMID: 32636728; PMCID: PMC7332812.
Copy Download .nbib Format: NLM
Feasibility assessment of in vitro chemoresponse assay on stereotactic biopsies of glioblastoma multiforms: a step towards personalized medicine.

Iranian journal of basic medical sciences

Sadeghi Fazel F, Haddadi M, Khoshnevisan A, Muhammadnejad S, Muhammadnejad A, Mazaheri Z, Arjomandnejad M, Shirkoohi R, Oghabian MA, Sherkat-Khameneh N, Amanpour S, Kazemimanesh M.
PMID: 25691936
Iran J Basic Med Sci. 2014 Nov;17(11):922-5.

OBJECTIVES: P In vitro chemosensitivity and resistance assays (CSRAs) are a promising tool for personalized treatment of glioblastoma multiform (GBM). These assays require a minimum of 1 to 2 g of tumor specimen for testing, but this amount is...

Cite
Sadeghi Fazel F, Haddadi M, Khoshnevisan A, et al. Feasibility assessment of in vitro chemoresponse assay on stereotactic biopsies of glioblastoma multiforms: a step towards personalized medicine. Iran J Basic Med Sci. 2014;17(11):922-5
Sadeghi Fazel, F., Haddadi, M., Khoshnevisan, A., Muhammadnejad, S., Muhammadnejad, A., Mazaheri, Z., Arjomandnejad, M., Shirkoohi, R., Oghabian, M. A., Sherkat-Khameneh, N., Amanpour, S., & Kazemimanesh, M. (2014). Feasibility assessment of in vitro chemoresponse assay on stereotactic biopsies of glioblastoma multiforms: a step towards personalized medicine. Iranian journal of basic medical sciences, 17(11), 922-5.
Sadeghi Fazel, Fariba, et al. "Feasibility assessment of in vitro chemoresponse assay on stereotactic biopsies of glioblastoma multiforms: a step towards personalized medicine." Iranian journal of basic medical sciences vol. 17,11 (2014): 922-5.
Sadeghi Fazel F, Haddadi M, Khoshnevisan A, Muhammadnejad S, Muhammadnejad A, Mazaheri Z, Arjomandnejad M, Shirkoohi R, Oghabian MA, Sherkat-Khameneh N, Amanpour S, Kazemimanesh M. Feasibility assessment of in vitro chemoresponse assay on stereotactic biopsies of glioblastoma multiforms: a step towards personalized medicine. Iran J Basic Med Sci. 2014 Nov;17(11):922-5. PMID: 25691936; PMCID: PMC4328103.
Copy Download .nbib Format: NLM
Synaptonemal Complex Protein 3 Transcript Analysis in Breast Cancer.

Iranian journal of public health

Mobasheri MB, Shirkoohi R, Modarressi MH.
PMID: 28053928
Iran J Public Health. 2016 Dec;45(12):1618-1624.

BACKGROUND: Breast cancer is the most frequent cancer in women. Cancer/Testis antigens are immunogenic proteins ectopically expressed in human neoplasms. Synaptonemal complex protein 3 (SYCP3) belongs to cancer/testis genes family involved in meiotic events and spermatogenesis. The aim of...

Cite
Mobasheri MB, Shirkoohi R, Modarressi MH. Synaptonemal Complex Protein 3 Transcript Analysis in Breast Cancer. Iran J Public Health. 2016;45(12):1618-1624
Mobasheri, M. B., Shirkoohi, R., & Modarressi, M. H. (2016). Synaptonemal Complex Protein 3 Transcript Analysis in Breast Cancer. Iranian journal of public health, 45(12), 1618-1624.
Mobasheri, Maryam Beigom, et al. "Synaptonemal Complex Protein 3 Transcript Analysis in Breast Cancer." Iranian journal of public health vol. 45,12 (2016): 1618-1624.
Mobasheri MB, Shirkoohi R, Modarressi MH. Synaptonemal Complex Protein 3 Transcript Analysis in Breast Cancer. Iran J Public Health. 2016 Dec;45(12):1618-1624. PMID: 28053928; PMCID: PMC5207103.
Copy Download .nbib Format: NLM
The association of vimentin and fibronectin gene expression with epithelial-mesenchymal transition and tumor malignancy in colorectal carcinoma.

EXCLI journal

Niknami Z, Eslamifar A, Emamirazavi A, Ebrahimi A, Shirkoohi R.
PMID: 28900381
EXCLI J. 2017 Jul 10;16:1009-1017. doi: 10.17179/excli2017-481. eCollection 2017.

Colorectal cancer is the most common malignancy of the gastrointestinal tract with very high mortality. One of the most distinguishing features for the establishment of an epithelial-mesenchymal transition phenotype is the alteration of mesenchymal markers expression and structural adhesion...

Cite
Niknami Z, Eslamifar A, Emamirazavi A, et al. The association of vimentin and fibronectin gene expression with epithelial-mesenchymal transition and tumor malignancy in colorectal carcinoma. EXCLI J. 2017;16:1009-1017doi: 10.17179/excli2017-481.
Niknami, Z., Eslamifar, A., Emamirazavi, A., Ebrahimi, A., & Shirkoohi, R. (2017). The association of vimentin and fibronectin gene expression with epithelial-mesenchymal transition and tumor malignancy in colorectal carcinoma. EXCLI journal, 161009-1017. https://doi.org/10.17179/excli2017-481
Niknami, Zohreh, et al. "The association of vimentin and fibronectin gene expression with epithelial-mesenchymal transition and tumor malignancy in colorectal carcinoma." EXCLI journal vol. 16 (2017): 1009-1017. doi: https://doi.org/10.17179/excli2017-481
Niknami Z, Eslamifar A, Emamirazavi A, Ebrahimi A, Shirkoohi R. The association of vimentin and fibronectin gene expression with epithelial-mesenchymal transition and tumor malignancy in colorectal carcinoma. EXCLI J. 2017 Jul 10;16:1009-1017. doi: 10.17179/excli2017-481. eCollection 2017. PMID: 28900381; PMCID: PMC5579408.
Copy Download .nbib Format: NLM
Evaluation of the indication of BRCA1/2 genetic tests in Iranian women and acceptance rate of risk-reducing surgeries in BRCA mutation carriers.

Molecular genetics & genomic medicine

Vasigh M, Eslami B, Elahi A, Kaviani A, Shirkoohi R, Majidzadeh K, Nazarian N, Omranipour R.
PMID: 35023322
Mol Genet Genomic Med. 2022 Jan 12;e1867. doi: 10.1002/mgg3.1867. Epub 2022 Jan 12.

BACKGROUND: A higher risk for breast and ovarian cancer has been reported in BRCA carriers and prophylactic surgeries are proposed to reduce this risk. This retrospective cohort study has evaluated the indication of BRCA1/2 genetic tests in Iranian women...

Cite
Vasigh M, Eslami B, Elahi A, et al. Evaluation of the indication of BRCA1/2 genetic tests in Iranian women and acceptance rate of risk-reducing surgeries in BRCA mutation carriers. Mol Genet Genomic Med. 2022;e1867doi: 10.1002/mgg3.1867.
Vasigh, M., Eslami, B., Elahi, A., Kaviani, A., Shirkoohi, R., Majidzadeh, K., Nazarian, N., & Omranipour, R. (2022). Evaluation of the indication of BRCA1/2 genetic tests in Iranian women and acceptance rate of risk-reducing surgeries in BRCA mutation carriers. Molecular genetics & genomic medicine, e1867. https://doi.org/10.1002/mgg3.1867
Vasigh, Mahtab, et al. "Evaluation of the indication of BRCA1/2 genetic tests in Iranian women and acceptance rate of risk-reducing surgeries in BRCA mutation carriers." Molecular genetics & genomic medicine vol. (2022): e1867. doi: https://doi.org/10.1002/mgg3.1867
Vasigh M, Eslami B, Elahi A, Kaviani A, Shirkoohi R, Majidzadeh K, Nazarian N, Omranipour R. Evaluation of the indication of BRCA1/2 genetic tests in Iranian women and acceptance rate of risk-reducing surgeries in BRCA mutation carriers. Mol Genet Genomic Med. 2022 Jan 12;e1867. doi: 10.1002/mgg3.1867. Epub 2022 Jan 12. PMID: 35023322.
Copy Download .nbib Format: NLM
Showing 25 to 31 of 31 entries